Small Molecule Drug Substance Pandemic Complications

Over the past two years, ISR has asked respondents to its annual small molecule drug substance benchmarking surveys whether they encountered pandemic related complications with their outsourced manufacturing. The data show it was slightly more common for small molecule API outsourcers to experience COVID-19 related manufacturing complications in 2021 than during 2020. To learn more about small molecule API manufacturers’ performance during the pandemic, follow the link to the Small Molecule API CMO Benchmarking report preview.